Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA - PEG nanoparticles

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 45, 2008, Pages 17356-17361

  Dhar, Shanta ^a   Gu, Frank X ^a,b   Langer, Robert ^a,b   Farokhza, Omid C ^a,c   Lippard, Stephen J ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Controlled release; DNA cross link; Metals in medicine; PSMA

Indexed keywords

APTAMER; CISPLATIN; MACROGOL; PLATINUM; POLYGLACTIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ARTICLE; CANCER CELL; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROSTATE CANCER;

APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; CISPLATIN; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MICROSCOPY, FLUORESCENCE; MOLECULAR STRUCTURE; NANOPARTICLES; NANOTECHNOLOGY; PLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; PRODRUGS; PROSTATIC NEOPLASMS;

EID: 56249097260     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0809154105     Document Type: Article

References (46)

1. Jemal A, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96.
2. Israeli RS, Powell CT, Fair WR, Heston WDW (1993) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53:227-230.
3. Murphy GP, et al. (1998) Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 83:2259-2269.
4. Kawakami M, Nakayama J (1997) Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 57:2321-2324.
5. Wright GL, Jr, et al. (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326-334.
6. Chang SS, et al. (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59:3192-3198.
7. Pinto JT, et al. (1996) Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2:1445-1451.
8. Rawlings ND, O'Brien E, Barrett AJ (2002) MEROPS: The protease database. Nucleic Acids Res 30:343-346.
9. Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99:2467-2498.
10. Rosenberg B, VanCamp L, Trosko JE, Mansour VH (1969) Platinum compounds: A new class of potent antitumour agents. Nature 222:385-386.
11. Nomura T, Mimata H (2007) Molecular mechanisms of cisplatin resistance in prostate cancer cells. Cancer Drug Resistance Perspectives, ed Torres LS, (Nova Science Publishers, New York), Vol. 121, pp 95-105.
12. Ferrari M (2005) Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer 5:161-171.
13. Langer R (1998) Drug delivery and targeting. Nature 392:5-10.
14. Langer R (2001) Drugs on target. Science 293:58-59.
15. Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Delivery Rev 56:1649-1659.
16. Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Delivery Rev 54:631-651.
17. Zhang L, et al. (2008) Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther 83:761-769.
18. LaVan DA, McGuire T, Langer R (2003) Small-scale systems for in vivo drug delivery. Nat Biotechnol 21:1184-1191.
19. Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505-515.
20. Gref R, et al. (1994) Biodegradable long-circulating polymer nanospheres. Science 263:1600-1603.
21. Fishburn CS (2008) The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. J Pharm Sci 97:4167-4183.
22. Barnes KR, Kutikov A, Lippard SJ (2004) Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem Biol 11:557-564.
23. Feazell RP, Nakayama-Ratchford N, Dai H, Lippard SJ (2007) Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J Am Chem Soc 129:8438-8439.
24. Dhar S, et al. (2008) Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J Am Chem Soc 130:11467-11476.
25. Mukhopadhyay S, et al. (2008) Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjugate Chem 19:39-49.
26. Farokhzad OC, et al. (2004) Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res 64:7668-7672.
27. Avgoustakis K, et al. (2002) PLGA-mPEG nanoparticles of cisplatin: In vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Controlled Release 79:123-135.
28. Fujiyama J, et al. (2003) Cisplatin incorporated in microspheres: Development and fundamental studies for its clinical application. J Controlled Release 89:397-408.
29. Stolnik S, et al. (2001) Polylactide-poly(ethylene glycol) micellar-like particles as potential drug carriers: Production, colloidal properties and biological performance. J Drug Targeting 9:361-378.
30. Moreno D, et al. (2008) Characterization of cisplatin cytotoxicity delivered from PLGA-systems. Eur J Pharm Biopharm 68:503-512.
31. Gryparis EC, Hatziapostolou M, Papadimitriou E, Avgoustakis K (2007) Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur J Pharm Biopharm 67:1-8.
32. Giandomenico CM, et al. (1995) Carboxylation of kinetically inert platinum(IV) hydroxy complexes. An entrée into orally active platinum(IV) antitumor agents. Inorg Chem 34:1015-1021.
33. Lupold SE, Hicke BJ, Lin Y, Coffey DS (2002) Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 62:4029-4033.
34. Farokhzad OC, et al. (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103:6315-6320.
35. Chorny M, Fishbein I, Danenberg HD, Golomb G (2002) Lipophilic drug loaded nanospheres prepared by nanoprecipitation: Effect of formulation variables on size, drug recovery and release kinetics. J Controlled Release 83:389-400.
36. Kopecek J, et al. (2001) Water soluble polymers in tumor targeted delivery. J Controlled Release 74:147-158.
37. Yoo HS, Lee KH, Oh JE, Park TG (2000) In vitro and in vivo antitumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Controlled Release 68:419-431.
38. Yokoyama M, et al. (1998) Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor. J Controlled Release 50:79-92.
39. Sengupta S, et al. (2005) Temporal targeting of tumor cells and neovasculature with a nanoscale delivery system. Nature 436:568-572.
40. Zhang Z, Feng S-S (2006) In vitro investigation on poly(lactide)-Tween 80 copolymer nanoparticles fabricated by dialysis method for chemotherapy. Biomacromolecules 7:1139-1146.
41. Milowsky MI, et al. (2007) Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 25:540-547.
42. Quintana JC, Blend MJ (2000) The dual-isotope ProstaScint imaging procedure: Clinical experience and staging results in 145 patients. Clin Nucl Med 25:33-40.
43. Liedert B, Pluim D, Schellens J, Thomale J (2006) Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res 34:e47.
44. Rieter WJ, Pott KM, Taylor KML, Lin W (2008) Nanoscale coordination polymers for platinum-based anticancer drug delivery. J Am Chem Soc 130:11584-11585.
45. Dhara SC (1970) A rapid method for the synthesis of cis-[Pt(NH3)2Cl2]. Indian J Chem 8:193-194.
46. Hall MD, et al. (2003) The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cells. J Biol Inorg Chem 8:726-732.